Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.56 |
| ▸ | ACHE | P22303 | 4/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653206 | 1.00 | DRD2 (0.56) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL3652078 | 0.94 | HTR2A (0.60) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL3652081 | 0.94 | HTR2A (0.60) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL3654185 | 0.88 | DRD2 (0.65) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL3653314 | 0.87 | DRD2 (0.47) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL3653318 | 0.87 | DRD2 (0.47) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL4312395 | 0.85 | CHRM3 (0.49) | SIGMAR1ACHEMEN1KMT2ACHRM3 | |
| SCHEMBL4312397 | 0.85 | CHRM3 (0.49) | SIGMAR1ACHEMEN1KMT2ACHRM3 | |
| SCHEMBL3560220 | 0.84 | HTR2A (0.55) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL3560218 | 0.84 | HTR2A (0.55) | DRD2HTR2AHTR2CHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200998-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009036117-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069370-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069370-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069370-A1 | AZACYCLYLISOQUINOLINONE AND ISOINDOLINONE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH1, HRH2 | DRD2 323/4885HTR2A 43/4885HTR2C 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.